Company Quick10K Filing
Crescent Acquisition Corp
10-Q 2019-09-30 Filed 2019-11-08
10-Q 2019-06-30 Filed 2019-08-09
10-Q 2019-03-31 Filed 2019-05-15
S-1 2019-02-15 Public Filing
8-K 2019-10-09
8-K 2019-04-15
8-K 2019-03-12
8-K 2019-03-07

Crescent Acquisition Corp Financials

CRSAU Metrics, Comps, Filings

Quarterly | Annual

Valuation ($)

Market Cap, Enterprise Value

Balance Sheet ($)

Assets, Equity

Income Statement ($ Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($ Quarterly)

Ops, Inv, Fin

Comps ($ TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Pacific Ventures (PACV) 0 25% -3.8 -65% 1,799,299,000 5,072,647,000 3,514,363,000 883,326,000 -1,171,232,000 -615,329,000 2,318,299,000
Galileo Acquisition (GLEO)
Gafisa (GFA)
VNUE (VNUE) 0 0% -2.0 -621% 167,934,000 3,665,522,000 200,234,000 0 -1,042,295,000 -633,550,000 1,242,340,000
New You (NWYU)
Angiosoma (SOAN) 0 64% -0.2 -475% 142,183,000 827,618,000 425,000 271,000 -675,072,000 -314,709,000 65,541,000
YaSheng Group (HERB)
Sprout Social (SPT)
Force Protection Video Equipment (FPVD) 0 56% 0.0 -394% 203,770,000 582,690,000 216,179,000 120,377,000 -802,223,000 -828,784,000 -1,188,000
United States Diesel-Heating Oil Fund (UHN) 0 0% -0.0 0 0 676,706,000 0 638,875,000 638,875,000 -1,000
FS Investment (FSIC)
XsunX (XSNX) 0 47% 0.1 1,089% 215,192,000 2,451,143,000 1,608,723,000 752,558,000 2,343,980,000 2,416,543,000 194,133,000
Nate's Food (NHMD) 0 92% -0.1 -6,857% 7,020,000 824,888,000 3,231,000 2,959,000 -481,373,000 -454,603,000 29,798,000
Crescent Acquisition Corp (CRSAU)
iGambit (IGMB) 0 -64% 0.0 -108% 2,104,777,000 1,464,845,000 20,793,000 -13,280,000 -2,269,396,000 -1,859,093,000 -10,030,000
Argentum 47 (ARGQ) 0 0% 0.0 -85% 1,486,956,000 2,004,523,000 86,582,000 0 -1,268,236,000 -1,187,094,000 -2,704,000
Regen Biopharma (RGBP) 0 0% -0.3 -4,777% 114,304,000 12,900,392,000 82,275,000 0 -5,460,658,000 -5,186,422,000 1,325,489,000
Kura Sushi (KRUS)
GH Capital (GHHC) 0 66% -0.0 -2,680% 88,588,000 330,870,000 211,072,000 138,571,000 -2,374,388,000 -2,374,388,000 59,127,000
Anchiano Therapeutics (ANCN)

Balance Sheet ($)
Cash
Accounts Receivable
Inventory
PP&E
Assets
Accounts Payable
Long-Term Debt
Liabilities
Stockholders' Equity
Income Statement ($)
Revenue
Cost of Revenue
Gross Profit
R&D
SG&A
Tax
Net Income
Cash Flow ($)
Cash Operating
Cash Investing
Cash Financing